A Case of Resistant Hypocalcemia Treated with Teriparatide
Open Access
- 7 March 2021
- journal article
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (Supplement), 92-93
- https://doi.org/10.46310/tjim.882244
Abstract
Postsurgical chronic hypoparathyroidism is most commonly seen in adults. Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions. Here we report a 52-year-old woman with postsurgical uncontrolled hypocalcemia despite the usual therapy. Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.Keywords
This publication has 7 references indexed in Scilit:
- Treating hypoparathyroidism with recombinant human parathyroid hormone (1–34): long-term safety concernsThe Lancet, 2020
- HypoparathyroidismThe New England Journal of Medicine, 2019
- Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal MorbidityJournal of Bone and Mineral Research, 2018
- Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future researchJournal of Bone and Mineral Research, 2011
- HypoparathyroidismThe New England Journal of Medicine, 2008
- Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidismJAMA, 1996
- Surgery for primary hyperparathyroidism: Experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patientBritish Journal of Surgery, 1982